更多栏目
首页 列表页面
阿诺医药完成逾5000万美元B轮融资
本轮融资由元明资本独家领投,经纬中国、德同资本与雅惠投资参与投资。
READ MORE
新闻
6月25日要闻一览
每日要闻
READ MORE
新闻
赛诺菲公布Toujeo®和degludec胰岛素的头对头研究结果
Toujeo (insulin glargine injection 300 Units/mL) met primary endpoint in lowering blood sugar levels and was non-inferior to insulin degludec in adults with type 2 diabetes not previously on insulin
READ MORE
新闻
AbbVie和Calibr宣布合作开发下一代CAR-T疗法
Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors
READ MORE
新闻
FDA接受默沙东KEYTRUDA®(派姆单抗)作为晚期黑色素...
Application Based on Recurrence-Free Survival Data from Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial
READ MORE
新闻
罗氏TECENTRIQ用于小细胞肺癌的临床试验数据积极
IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer (ES-SCLC)
READ MORE
新闻
论审评员的修养 | 正见
用匠人精神撰写审评报告。
READ MORE
正见
真实世界数据显示,Tresiba®与甘精胰岛素U300相比可...
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin
READ MORE
新闻
Xultophy®在用作补充口服糖尿病药物时,与甘精胰岛素...
Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks
READ MORE
新闻
口服索马鲁肽在PIONEER 1试验中显示血糖显着降低
Two distinct approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 1 trial
READ MORE
新闻
Copyright © 2016-2020 研发客.All Rights Reserved.
建议反馈: Support@PharmaDJ.com
备案/许可证编号: 沪ICP备17054709号
联系电话:021 - 88194359